Vivus Evamist Menopause Spray To Start Phase III Under Special Protocol Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will conduct single 12-week trial for treatment of moderate to severe vasomotor symptoms with the transdermal estradiol spray. Evamist would be the first estradiol topical spray formulation, Vivus says.
You may also be interested in...
Vivus Could File Evamist Menopause Spray By Year-End
Transdermal estradiol spray significantly reduces hot flashes in Phase III trial.
Vivus Could File Evamist Menopause Spray By Year-End
Transdermal estradiol spray significantly reduces hot flashes in Phase III trial.
P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005
NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.